GMAB

NASD Genmab A/S Sponsored ADR
Oct 7, 2026 · 2:01 PM ET DELAYED Market Open

$36.89 ↓ -0.91 (-2.41%) Trading Down from the previous close of $37.80, $0.98 below the day’s high of $37.87

YTD change
+19.77%
vs 20-day SMA
+6.13%
vs 200-day SMA
+24.24%

Price ranges

Previous day
$37.07 $39.15
open $39.11 close $37.80
-$1.31 (-3.35%)
Today
$36.72 $37.87
open $37.30 now $36.89
-$0.41 (-1.10%)
Past week
$33.73 $40.17
from $35.57 now $36.89
+$1.32 (+3.71%)
Past month
$32.21 $40.17
from $33.53 now $36.89
+$3.36 (+10.02%)
This year
$23.62 $40.17
from $30.80 now $36.89
+$6.09 (+19.77%)

Price & Performance

+10.15 (+36.71%) / 6M

$22.68$28.34$33.99$39.65Apr 7Jul 8Oct 6

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Neutral
  • The stock is 24.8% away from all-time highs of $49.07
  • GMAB is up 20% since the beginning of the year
  • GMAB is up 13% over the past 12 months
  • GMAB is up 10% over the past 1 month
  • 1% of all GMAB investors are betting against GMAB

GMAB reads neutral: price sits above both the 20- and 200-day averages, the 12-month move is +15.8%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable Yes
EPS $0.491
Earnings momentum -41.8% Quarterly EPS growth
Quarterly change -41.8%

Valuation

P/E ratio N/A
Enterprise value $27.1B
Beta 0.70

Balance sheet & scale

Income$787.1K
Revenue$4.1B
Cash$1.5B
Debt$5.3M
Income / Debt 0.15×

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Manufacturing
Sub Sector Chemical Manufacturing
Market cap $22.0B

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

Competitor comparison

TickerCompany PriceChange
LLY Eli Lilly and Company $1,157.49 +1.26%
JNJ Johnson & Johnson $254.78 +0.73%
ABBV AbbVie, Inc. $266.69 +0.35%
MRK Merck & Co., Inc. $141.94 +1.72%
RHHVF Roche Holding Ltd $427.38 -0.12%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.